BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

...vaccine Infectious Disease Research Institute; Aeras Phase I W805EC Oil-in-water emulsion NB-1008, an influenza vaccine NanoBio...
BioCentury | Mar 31, 2014
Company News

NanoBio, Merck deal

...NanoBio granted Merck exclusive, worldwide rights to NanoBio's nanoemulsion-based adjuvant technology for use in an intranasal...
...vaccine. NanoBio will receive an upfront payment and is eligible to receive milestones and royalties. NanoBio's...
...can incorporate, deliver and adjuvant multiple antigen types. The partners declined to disclose financial details. NanoBio...
BioCentury | Dec 3, 2012
Financial News

NanoBio completes venture financing

NanoBio Corp. , Ann Arbor, Mich. Business: Infectious Date completed: 11/28/12 Type: Venture financing Raised: $11 million Investors: Existing investors WIR Staff Infectious...
BioCentury | Nov 12, 2012
Company News

NanoBio, Health Protection Agency (HPA), NIH infectious, drug delivery news

...£4 million ($6.4 million) contract to develop a next-generation anthrax vaccine . HPA will use NanoBio's...
...NanoBio is HPA's subcontractor for the work and will own rights to any background IP. NanoBio...
...antigen for animal and human testing. The biotech is receiving undisclosed funding for the work. NanoBio...
BioCentury | Oct 15, 2012
Company News

NanoBio management update

NanoBio Corp. , Ann Arbor, Mich. Business: Infectious Departed: Co-founder and CEO James Baker, while remaining a director, to become SVP of head global vaccine franchise at Merck & Co. Inc. ; he is replaced by...
BioCentury | Oct 10, 2012
Company News

NanoBio CEO leaves to head Merck vaccine franchise

...franchise. NanoBio promoted David Peralta to CEO from COO and CFO. Baker will remain on NanoBio's...
...promoted David Peralta to CEO from COO and CFO. Baker will remain on NanoBio's board. NanoBio...
...dermatology products, anti-infective treatments and intranasal vaccines based on its NanoStat technology. In December 2011, NanoBio...
BioCentury | Dec 19, 2011
Company News

NanoBio, Merck deal

...The partners will evaluate combining Merck's respiratory syncytial virus (RSV) antigen and NanoBio's NanoStat adjuvant technology...
...NanoBio's NanoStat adjuvant technology to develop a commercial RSV vaccine . Terms were not disclosed. NanoBio...
BioCentury | Sep 5, 2011
Clinical News

NanoBio preclinical data

...In mice, vaccination with NanoBio's intranasal nanoemulsion-adjuvanted inactivated respiratory syncytial virus (RSV) vaccine significantly increased levels...
...One. Last month, NanoBio received exclusive, worldwide rights from NIH to an antigen against RSV. NanoBio...
...technology with the antigen for use in the company's RSV vaccine (see BioCentury, Aug. 8). NanoBio...
BioCentury | Aug 8, 2011
Company News

NanoBio deal

...NanoBio received exclusive, worldwide rights from NIH to an antigen against respiratory syncytial virus (RSV). NanoBio...
...the development of the RSV vaccine. Details were not disclosed (see BioCentury, Dec. 6, 2010). NanoBio...
BioCentury | Jul 4, 2011
Clinical News

Nanoemulsion-adjuvanted influenza vaccine: Phase Ib started

...a sprayer device and a pipette dropper vs. Fluzone from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). NanoBio...
Items per page:
1 - 10 of 50
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

...vaccine Infectious Disease Research Institute; Aeras Phase I W805EC Oil-in-water emulsion NB-1008, an influenza vaccine NanoBio...
BioCentury | Mar 31, 2014
Company News

NanoBio, Merck deal

...NanoBio granted Merck exclusive, worldwide rights to NanoBio's nanoemulsion-based adjuvant technology for use in an intranasal...
...vaccine. NanoBio will receive an upfront payment and is eligible to receive milestones and royalties. NanoBio's...
...can incorporate, deliver and adjuvant multiple antigen types. The partners declined to disclose financial details. NanoBio...
BioCentury | Dec 3, 2012
Financial News

NanoBio completes venture financing

NanoBio Corp. , Ann Arbor, Mich. Business: Infectious Date completed: 11/28/12 Type: Venture financing Raised: $11 million Investors: Existing investors WIR Staff Infectious...
BioCentury | Nov 12, 2012
Company News

NanoBio, Health Protection Agency (HPA), NIH infectious, drug delivery news

...£4 million ($6.4 million) contract to develop a next-generation anthrax vaccine . HPA will use NanoBio's...
...NanoBio is HPA's subcontractor for the work and will own rights to any background IP. NanoBio...
...antigen for animal and human testing. The biotech is receiving undisclosed funding for the work. NanoBio...
BioCentury | Oct 15, 2012
Company News

NanoBio management update

NanoBio Corp. , Ann Arbor, Mich. Business: Infectious Departed: Co-founder and CEO James Baker, while remaining a director, to become SVP of head global vaccine franchise at Merck & Co. Inc. ; he is replaced by...
BioCentury | Oct 10, 2012
Company News

NanoBio CEO leaves to head Merck vaccine franchise

...franchise. NanoBio promoted David Peralta to CEO from COO and CFO. Baker will remain on NanoBio's...
...promoted David Peralta to CEO from COO and CFO. Baker will remain on NanoBio's board. NanoBio...
...dermatology products, anti-infective treatments and intranasal vaccines based on its NanoStat technology. In December 2011, NanoBio...
BioCentury | Dec 19, 2011
Company News

NanoBio, Merck deal

...The partners will evaluate combining Merck's respiratory syncytial virus (RSV) antigen and NanoBio's NanoStat adjuvant technology...
...NanoBio's NanoStat adjuvant technology to develop a commercial RSV vaccine . Terms were not disclosed. NanoBio...
BioCentury | Sep 5, 2011
Clinical News

NanoBio preclinical data

...In mice, vaccination with NanoBio's intranasal nanoemulsion-adjuvanted inactivated respiratory syncytial virus (RSV) vaccine significantly increased levels...
...One. Last month, NanoBio received exclusive, worldwide rights from NIH to an antigen against RSV. NanoBio...
...technology with the antigen for use in the company's RSV vaccine (see BioCentury, Aug. 8). NanoBio...
BioCentury | Aug 8, 2011
Company News

NanoBio deal

...NanoBio received exclusive, worldwide rights from NIH to an antigen against respiratory syncytial virus (RSV). NanoBio...
...the development of the RSV vaccine. Details were not disclosed (see BioCentury, Dec. 6, 2010). NanoBio...
BioCentury | Jul 4, 2011
Clinical News

Nanoemulsion-adjuvanted influenza vaccine: Phase Ib started

...a sprayer device and a pipette dropper vs. Fluzone from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). NanoBio...
Items per page:
1 - 10 of 50